Trial Condition(s):

Atrial Fibrillation

Survey on Belgian patients suffering from irregular heartbeat and starting treatment with a drug to prevent blood clots in blood vessels and the heart. This study is also called BELANCOS. (BELANCOS)

Bayer Identifier:

21153

ClinicalTrials.gov Identifier:

NCT04183270

EudraCT Number:

Not Available

Study Completed

Trial Purpose

In this study researchers want to learn more about the patient’s and treating doctor’s concerns about possible bleedings during treatment with drugs preventing blood clots in blood vessels and the heart – so called blood thinner. The study also wants to find out more about the patient’s knowledge on the importance, risks and benefits of treatment with this drug group.
Patients with irregular heartbeat not caused by valvular heart disease who will start treatment with a blood thinner will be asked by their treating cardiologist to complete a questionnaire related to their knowledge and fear of possible bleedings or stroke (blockage or rupture of a blood vessel to the brain) due to the intake of a blood thinner. The treating doctor will complete a similar questionnaire. The study plans to involve 15 cardiologists and 300 patients in Belgium.

Inclusion Criteria
- Male or female adult patients diagnosed with NVAF.
- NOAC treatment-naive patients who will start a NOAC treatment.
Exclusion Criteria
- Previous stroke or thrombosis
- Previous severe bleeding

Trial Summary

Enrollment Goal
164
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Unspecified
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Many locations

Many locations, Belgium

Status
Completed
 

Trial Design